Can­del to fo­cus on non-squa­mous lung can­cer fol­low­ing new sur­vival da­ta

Can­del Ther­a­peu­tics said Wednes­day that new da­ta on its vi­ral im­munother­a­py showed on­ly a mar­gin­al im­prove­ment in sur­vival of pro­gres­sive lung can­cer pa­tients com­pared with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER